CA3176944A1 - 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer - Google Patents
5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancerInfo
- Publication number
- CA3176944A1 CA3176944A1 CA3176944A CA3176944A CA3176944A1 CA 3176944 A1 CA3176944 A1 CA 3176944A1 CA 3176944 A CA3176944 A CA 3176944A CA 3176944 A CA3176944 A CA 3176944A CA 3176944 A1 CA3176944 A1 CA 3176944A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- pyrimidin
- triazolo
- pyridy1
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994908P | 2020-03-26 | 2020-03-26 | |
| US62/994,908 | 2020-03-26 | ||
| PCT/EP2021/057806 WO2021191378A1 (en) | 2020-03-26 | 2021-03-25 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3176944A1 true CA3176944A1 (en) | 2021-09-30 |
Family
ID=75339740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3176944A Pending CA3176944A1 (en) | 2020-03-26 | 2021-03-25 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230271964A1 (enExample) |
| EP (1) | EP4126872A1 (enExample) |
| JP (1) | JP7675094B2 (enExample) |
| KR (1) | KR20230049579A (enExample) |
| CN (1) | CN115867282B (enExample) |
| AU (1) | AU2021240344A1 (enExample) |
| CA (1) | CA3176944A1 (enExample) |
| WO (1) | WO2021191378A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20241731A1 (es) * | 2022-02-01 | 2024-08-19 | Lilly Co Eli | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| EP2038285B1 (en) | 2006-06-26 | 2010-02-17 | Schering Corporation | Adenosine a2a receptor antagonists |
| JP2011513417A (ja) * | 2008-03-04 | 2011-04-28 | シェーリング コーポレイション | アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物 |
| CN103261202B (zh) | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| KR20190129851A (ko) | 2017-03-16 | 2019-11-20 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도 |
-
2021
- 2021-03-25 WO PCT/EP2021/057806 patent/WO2021191378A1/en not_active Ceased
- 2021-03-25 EP EP21715861.7A patent/EP4126872A1/en active Pending
- 2021-03-25 AU AU2021240344A patent/AU2021240344A1/en active Pending
- 2021-03-25 JP JP2022558347A patent/JP7675094B2/ja active Active
- 2021-03-25 KR KR1020227037221A patent/KR20230049579A/ko not_active Ceased
- 2021-03-25 US US17/914,245 patent/US20230271964A1/en not_active Abandoned
- 2021-03-25 CA CA3176944A patent/CA3176944A1/en active Pending
- 2021-03-25 CN CN202180038001.3A patent/CN115867282B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7675094B2 (ja) | 2025-05-12 |
| EP4126872A1 (en) | 2023-02-08 |
| AU2021240344A1 (en) | 2022-10-27 |
| CN115867282B (zh) | 2025-05-27 |
| CN115867282A (zh) | 2023-03-28 |
| KR20230049579A (ko) | 2023-04-13 |
| US20230271964A1 (en) | 2023-08-31 |
| JP2023519362A (ja) | 2023-05-10 |
| WO2021191378A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019267008B2 (en) | Tetracyclic heteroaryl compounds | |
| AU2021411587B2 (en) | Indazole compounds as kinase inhibitors | |
| US10005774B2 (en) | Syk inhibitors | |
| KR101862493B1 (ko) | Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체 | |
| AU2022232523A1 (en) | Kras g12d inhibitors | |
| CA3217856A1 (en) | Heterocyclic compounds and methods of use | |
| AU2021401232A9 (en) | Azaquinazoline pan-kras inhibitors | |
| JP7675094B2 (ja) | トリアゾロン化合物 | |
| KR20230049580A (ko) | 트리아졸론 화합물 | |
| WO2021191379A1 (en) | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | |
| KR20250008781A (ko) | NF-κB 유도 키나제의 억제제로서의 피롤리디논 유도체 | |
| TW202504586A (zh) | 治療發炎性疾病之方法 | |
| HK1224672B (en) | Syk inhibitors | |
| HK1224672A1 (en) | Syk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240705 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241023 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250102 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250102 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250317 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250512 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260303 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260506 |